CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Friday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Performance

Shares of CVM stock opened at $0.23 on Friday. CEL-SCI has a 12 month low of $0.18 and a 12 month high of $2.22. The company’s fifty day simple moving average is $0.25 and its 200-day simple moving average is $0.43. The firm has a market cap of $19.46 million, a PE ratio of -0.48 and a beta of 0.50. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC increased its stake in shares of CEL-SCI Co. (NYSE:CVM) by 40.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 191,661 shares of the company’s stock after acquiring an additional 54,900 shares during the period. Thoroughbred Financial Services LLC owned about 0.26% of CEL-SCI worth $76,000 as of its most recent filing with the SEC. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.